Rationale and design of a European epidemiological post-authorization safety study (PASS) program: rivaroxaban use in routine clinical practice.
作者:
主题词
药物副反应报告系统(Adverse Drug Reaction Reporting Systems);病例对照研究(Case-Control Studies);队列研究(Cohort Studies);数据库, 事实型(Databases, Factual);欧洲(Europe);人类(Humans);产品监测, 售后(Product Surveillance, Postmarketing);研究设计(Research Design)
DOI
10.1080/14740338.2020.1798928
PMID
32700977
发布时间
2021-03-11
- 浏览2

Expert opinion on drug safety
1513-1520页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文